Medical benefit drug spending jumps 21 percent in one year
This year’s report shows that in 2016, commercial health plans’ per-member per-month (PMPM) medical benefit pharmacy trend underwent the largest jump in five years due to rapidly evolving market dynamics and increases in drug pricing.
“The commercial PMPM trend was at an all-time high—21 percent—a 62
percent difference over the 13 percent average annual trend of the last
five years,” according to
Noteworthy new analyses this year found that only 10 percent of
commercial patients and 21 percent of
“New entrants, programmed-cell death (PD)-1 inhibitors Opdivo
(nivolumab) and Keytruda (pembrolizumab) played a significant role in
the 2016 medical benefit drug trend,” according to Stockman. “Most
notably, Opdivo entered the top five drugs by spend for
Other key highlights from the Medical Pharmacy Trend Report:
Commercial PMPM increased 21 percent to
$26.26in 2016, besting the five-year average trend of 13 percent. Medicarehad a three percent increase in PMPM to $46.97, on par with the four percent five-year average trend.
- Eight of the top 20 commercial disease states, or drug categories, have more than doubled in spend over the last five years.
- Sixty-eight percent of payers are now using a site of service program, and more than 50 percent of payers are employing some form of dose optimization protocols.
- Oncology immunotherapy costs could potentially increase 231 percent over the next five years.
- More than 94 percent of plans will be capturing, storing and/or reporting national drug code (NDC) information by 2019.
“Overall, we learned the medical benefit trend continues to outpace the pharmacy benefit trend,” said Stockman. “Over the last five years, the average annual commercial medical benefit trend was 13 percent while the pharmacy trend was closer to five percent, reinforcing the need to diligently manage drugs covered by the medical benefit to help temper the accelerating costs.”
Key strategies for the effective management of medical benefit drug spend outlined in the report include:
- Clinically and operationally managing new drugs to market and drugs billed with unclassified Healthcare Common Procedure Coding System (HCPCS) codes and diligent management of the drug pipeline;
- Improving claims system capabilities to capture and report National Drug Codes;
- Managing high cost medical pharmacy therapies with targeted programs;
- Exploring unique strategies such as dose optimization and site of service management;
- Employing provider network strategies for commercial members to remove disparities in cost by outpatient place of service; and
- Making medical benefit drug costs and therapeutic options more transparent to members.
“With the growing impact of the specialty drug market, it is crucial that health plans have a strong infrastructure and robust management framework for medical benefit drugs to control escalating spend and improve quality outcomes,” said Stockman.
The report is based on survey responses from medical, pharmacy and
network directors from 46 commercial and
Magellan Rx Management is a full-service, next generation,
pharmacy benefit manager (PBM) with a value-driven approach that moves
past the traditional volume-focused thinking to deliver meaningful
solutions. Our services expand beyond traditional core services to help
our customers and members solve complex pharmacy challenges by
connecting them to the people, technology and information they need to
make smarter healthcare decisions. As pioneers in managing specialty
spend both on the prescription and medical benefit, we are
effectively-positioned to continue delivering thought-leading solutions
in this complex and rapidly growing area of healthcare to help people
live healthier lives. Magellan Rx Management is a division of
About Magellan Health, Inc.: